US-based LinusBio, a leader in precision exposome medicine, has announced that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio.
This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally.
ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, non-invasive approach provides healthcare providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development.
The Japanese launch builds on ClearStrand-ASD’s successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate the implementation of this first-of-its-kind biomarker test for autism.
LinusBio's expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio's scaling efforts globally.
